Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.

Source: Gut 2023 Feb 02; . doi: 10.1136/gutjnl-2022-328387Authors: Wagner F, Mansfield JC, Lekkerkerker AN, Wang Y, Keir M, Dash A, Butcher B, Harder B, Orozco LD, Mar JS, Chen H, Rothenberg ME

The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG for improved pharmacokinetic characteristics, but with a mutation to minimise Fc effector functions.

Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36732049?dopt=Abstract